Wynn: Analysts' New Targets, Estimates

Wynn Resorts shares now seen reaching $90 at Citigroup, given better expected growth in Macau.
Author:
Publish date:

Click here for Analysts' Upgrades, Downgrades.

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (

TheStreet

) --

STOCK COMMENTS / EPS CHANGES

Wynn Resorts

(WYNN) - Get Report

numbers raised at Citigroup. Shares of WYNN now seen reaching $90, according to Citigroup. Estimates also increased, given better expected growth in Macau. Sell rating.

Wynn Resorts target, estimates boosted at Barclays. WYNN price target raised to $90 from $84. Strong third-quarter results highlighted by Macau operations, Barclays said. 2010 and 2011 EPS estimates lifted to $1.59 and $2.39, respectively. Maintain Neutral rating.

AmerisourceBergen

(ABC) - Get Report

estimates, target raised at Oppenheimer.Shares of ABC now seen reaching $37, according to Oppenheimer. Estimates also increased, as the company should benefit from a strong generics pipeline. Outperform rating.

Agco

(AGCO) - Get Report

estimates, target raised at UBS. Shares of AGCO now seen reaching $41, according to UBS. Estimates also increased, to match the company's new guidance. Sell rating.

American Superconductor

(AMSC) - Get Report

numbers increased at Jefferies. AMSC estimates were raised through 2011, Jefferies said. Company boosted its guidance. Buy rating and new $42 price target.

Alpha Natural

(ANR)

estimates cut at Citigroup through 2011. Company is facing higher costs across the board. Buy rating and new $55 price target.

Anadarko Petroleum

(APC) - Get Report

price target increased at Barclays to $71 from $66. Strong operating results in third quarter, Barclays said. 2010 and 2011 EPS estimates reduced to $1.55 and $0.80, respectively. Maintain Overweight rating.

Biogen Idec

(BIIB) - Get Report

estimates were raised through 2012, Jefferies said. Restructuring plan should boost earnings. Buy rating and new $63 price target.

Bridgepoint Education

(BPI) - Get Report

price target cut at Credit Suisse to $16 from $20. Results better than peers, but regulatory uncertainties persist, Credit Suisse said. Maintain Neutral rating.

Career Education

(CECO) - Get Report

price target trimmed at Credit Suisse to $15 from $19. Third-quarter results highlighted by uncertainty, Credit Suisse said. Maintain Neutral rating.

Career Education numbers lowered at UBS. Shares of CECO now seen reaching $19, according to UBS. Estimates also cut, given limited earnings visibility. Neutral rating.

Carefusion

(CFN)

estimates, target lowered at Goldman. CFN estimates were cut through 2013, Goldman Sachs said. Company is seeing lower demand for respiratory care and infusion pumps. Buy rating and new $28 price target.

Clean Harbors

(CLH) - Get Report

price target increased at Credit Suisse. CLH price target raised to $86 from $74. Base business improving and Eveready prospects are looking good, Credit Suisse said. Maintain Outperform rating.

Clorox

(CLX) - Get Report

estimates, target reduced at Oppenheimer. Shares now seen reaching $70, according to Oppenheimer. Estimates also cut, because of lower domestic sales. Outperform rating.

Con-way

(CNW)

estimates, target upped at Goldman. CNW estimates were boosted through 2012, Goldman Sachs said. Better pricing is driving the company's margins higher. Neutral rating and new $34 price target.

Corinthian Colleges

(COCO)

price target cut at Barclays. COCO price target trimmed to $5 from $7 as significant challenges remain, Barclays said. Maintain Equal Weight rating.

Cooper Tire

(CTB) - Get Report

numbers increased at Morgan Stanley. CTB estimates were raised through 2011, Morgan Stanley said. Company is realizing higher margins, aided by increased efficiencies. Overweight rating and new $26 price target.

Covance

(CVD)

estimates, target upped at Goldman. CVD estimates were upped through 2012, Goldman Sachs said. Company continues to cut costs. Neutral rating and new $46 price target.

CVS Caremark

(CVS) - Get Report

numbers lowered at Citigroup. Shares of CVS now seen reaching $41, according to Citigroup. Estimates also reduced, to match the company's new guidance. Buy rating.

Concho Resources

(CXO) - Get Report

numbers raised at UBS. Shares of CXO now seen reaching $80, according to UBS. Estimates also increased, because of higher production rates. Buy rating and new $80 price target.

Dean Foods

(DF) - Get Report

numbers raised at Goldman Sachs. Shares of DF now seen reaching $11, according to Goldman Sachs. Estimates also increased, given lower corporate costs. Neutral rating.

Amdocs

(DOX) - Get Report

estimates, target reduced at Goldman Sachs. DOX estimates were cut through 2012, Goldman Sachs said. New CEO has reset margin expectations. Buy rating and new $32 price target.

Consolidated Edison

(ED) - Get Report

numbers raised at Oppenheimer. Shares of ED now seen reaching $49, according to Oppenheimer. Estimates also increased, given lower debt costs. Perform rating.

Emerson Electric

(EMR) - Get Report

numbers boosted at Citigroup. Shares of EMR now seen reaching $54, according to Citigroup. Estimates also upped, given better organic growth. Hold rating.

EOG Resources

(EOG) - Get Report

cut from Conviction Buy List at Goldman Sachs. EOG was removed from the Conviction Buy list, Goldman Sachs said. Midstream and fracture delays will hurt production. New $110 price target.

EOG Resources

(EOG) - Get Report

estimates lowered at Morgan Stanley. EOG estimates were cut through 2012, Morgan Stanley said. Company reduced its production guidance. Equal-weight rating.

Expeditors International of Washington

(EXPD) - Get Report

price target boosted at Credit Suisse. EXPD price target lifted to $61 from $54. Margin expansion to drive next phase of profit growth, Credit Suisse said. Maintain Outperform rating.

Garmin

(GRMN) - Get Report

estimates, target increased at Goldman Sachs. GRMN estimates were raised through 2012, Goldman Sachs said. Higher non-navigation sales are driving better earnings. Neutral rating and new $30 price target.

Genesee & Wyoming

(GWR) - Get Report

price target higher at Credit Suisse. GWR price target improved to $55 from $53 on solid third-quarter results. GWE focused on investment opportunities that will increase it exposure to rising demand for iron ore and minerals from emerging Asia, Credit Suisse said. Maintain Outperform rating.

Kellogg

(K) - Get Report

2010 EPS estimate raised slightly to $3.27 at Barclays. 2011 EPS estimate cut to $3.44. Cautious guidance, Barclays noted. Maintain Neutral rating and $56 price target.

Kellogg estimates were cut through 2011 at Goldman Sachs. Company is seeing softer sales. Neutral rating and $51 price target.

MasterCard

(MA) - Get Report

target, estimates boosted at Barclays. MA price target increased to $305 from $272. Company at compelling infection point on deconversions, Barclays said. 2010 and 2011 EPS estimates lifted to $13.96 and $17, respectively.

Mastercard estimates, target were boosted through 2012 at Goldman Sachs. Company is seeing higher global volume growth. Buy rating and new $285 price target.

MGM Resorts

(MGM) - Get Report

price target cut at Barclays by a dollar to $18. Vegas poised for improvement, but MGM still faces challenges, Barclays said. 2010 and 2011 EPS estimates lowered to -$1.11 and -$0.5, respectively. Maintain Overweight rating.

MGM Resorts numbers boosted at Jefferies. Shares of MGM now seen reaching $13, according to Jefferies. Estimates also upped, given better Las Vegas results. Hold rating.

Morgans Hotel Group

(MHGC)

target higher, estimates changed at Credit Suisse.MHGC price target increased by a dollar to $11. The New York City recovery led third-quarter results, Credit Suisse said. 2010 EPS estimate lowered to -$3.49, 2011 raised to -$1.03. Maintain Outperform rating.

Medco Health

(MHS)

numbers upped at Citigroup. MHS estimates were boosted through 2011, Citigroup said. Company is realizing higher margins. Buy rating and new $74 price target.

Medco Health Solutions estimate raised at Barclays. MHS 2011 EPS estimate increased to $4.07, 2010 maintained at $3.40. Reiterate Overweight rating and $69 price target.

Medco Health numbers increased at Goldman Sachs. MHS estimates were raised through 2013, Goldman Sachs said. Company is seeing a greater generic benefit. Buy rating and new $68 price target.

Myriad Genetics

(MYGN) - Get Report

estimates were boosted through 2013, Morgan Stanley said. Company is benefiting from improved utilization. Equal-weight rating.

NYSE Euronext

(NYX)

estimates were lowered through 2011, UBS said. Company is guiding to higher costs and not buying back as many shares. Buy rating and new $38 price target.

NYSE Euronext numbers were raised through 2012, Goldman Sachs said. Company is seeing better tech revenue and paying lower taxes. Neutral rating and new $33 price target.

OpenTable

(OPEN)

estimates boosted through 2012, according to Morgan Stanley. Company's continues to post accelerated growth. Equal-weight rating.

Pfizer

(PFE) - Get Report

estimates were boosted through 2011, UBS said. Company is benefiting from currency rates. Buy rating and $21 price target.

Principal Financial

(PFG) - Get Report

estimates were boosted through 2012, Goldman Sachs said. Company is likely to repurchase shares. Buy rating and $31 price target.

Pulte Group

(PHM) - Get Report

estimates were cut through 2012, Goldman Sachs said. Company is realizing lower margins and facing higher write-downs. Neutral rating and new $8 price target.

Perrigo

(PRGO) - Get Report

estimates, target boosted at Goldman Sachs. Shares of PRGO now seen reaching $52, according to Goldman Sachs. Estimates also upped, as higher sales is driving margin growth. Sell rating.

Prudential

(PRU) - Get Report

price target boosted at Barclays to $64 from $61. So far earnings are strong, but investor call is the main event, Barclays said. 2010 and 2011 EPS estimates lifted to $5.90 and $6.43, respectively.

Par Pharmaceutical

(PRX)

numbers boosted at Goldman Sachs. Shares now seen reaching $34, according to Goldman Sachs. Estimates also upped, as higher sales are driving wider margins. Neutral rating.

Quanta Services

(PWR) - Get Report

numbers cut at Goldman Sachs. Shares now seen reaching $19, according to Goldman Sachs. Estimates also lowered, because of declining earnings quality. Neutral rating.

Qualcomm

(QCOM) - Get Report

price target lifted at Credit Suisse to $50 from $40. Recovery already priced in, Credit Suisse said. Maintain Neutral rating.

Qualcomm estimates, target raised at Goldman Sachs. Shares of QCOM now seen reaching $58, according to Goldman Sachs. Estimates also increased, given continued growth in smartphone sales. Buy rating.

Qlik Technologies

(QLIK)

numbers boosted at Jefferies. Shares now seen reaching $29, according to Jefferies. Estimates also upped, as the company is taking market share. Buy rating.

Regal Entertainment

(RGC)

estimates upped at Morgan Stanley through 2012. Cost-cutting is offsetting lower sales. Underweight rating and $13 price target.

Solera

(SLR)

estimates, target boosted at Goldman Sachs. Shares now seen reaching $51, according to Goldman Sachs. Estimates also upped, given solid earnings momentum. Neutral rating.

SM Energy

(SM) - Get Report

estimates, target boosted at UBS. Shares now seen reaching $43, according to UBS. Estimates also upped, given better liquids demand. Neutral rating.

Sykes Enterprises

(SYKE) - Get Report

target, estimates raised at Credit Suisse. SYKE price target increased by a dollar to $16. Solid third-quarter and strong fourth-quarter guidance reflects improving outlook, Credit Suisse said. 2010 and 2011 ERPS estimates lifted to $1.07 and $1.24, respectively. Maintain Neutral rating

Molson Coors

(TAP) - Get Report

numbers increased at Goldman Sachs through 2012. Company is seeing higher sales and facing lower costs in the U.S. Neutral rating and new $51 price target.

Tenet Healthcare

(THC) - Get Report

estimates lowered at Goldman Sachs through 2012. Company is seeing lower hospital admissions. Neutral rating and new $5 price target.

Trimble Navigation

(TRMB) - Get Report

numbers boosted at Oppenheimer. Shares of TRMB now seen reaching $43, according to Oppenheimer. Estimates also upped, as the company is seeing better demand from agriculture and construction customers. Outperform rating.

Time Warner

(TWX)

estimates increased at UBS through 2011. Company is benefiting from non-operating items. Buy rating and $36 price target.

Valueclick

(VCLK)

estimates raised at UBS. Shares of VCLK now seen reaching $15, according to UBS. Estimates also increased, given better media and affiliate marketing. Neutral rating.

Vishay

(VSH) - Get Report

estimates, target raised at Citigroup. Shares of VSH now seen reaching $15, according to Citigroup. Estimates also increased, given higher realized margins. Hold rating.

WebMD Health

(WBMD)

numbers raised at Goldman Sachs. Shares of WBMD now seen reaching $58, according to Goldman Sachs. Estimates also increased, because of better expected advertising growth. Neutral rating.

Whole Foods

(WFMI)

numbers raised at Citigroup. Shares of WFMI now seen reaching $48, according to Citigroup. Estimates also increased, as the company has solid sales momentum. Hold rating.

Whole Foods Market target, estimates boosted at Credit Suisse. WFMI price target raised to $37 from $30. Strong fourth-quarter 2010 results better than expected, Credit Suisse said. Maintain Underperform rating.

This article was written by a staff member of TheStreet.